Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib
暂无分享,去创建一个
T. Sand | E. Sugarman | Ronald W. Clark | Tamara A. Sutfin | Roger B. Ruggeri | Ann T. Willauer | Eliot D. Sugarman | George Magnus-Aryitey | Patricia G. Cosgrove | Thomas M. Sand | Ronald T. Wester | John A. Williams | Michael E. Perlman | Mark J. Bamberger | M. Bamberger | M. Perlman | R. Ruggeri | R. T. Wester | R. Clark | G. Magnus-Aryitey | T. Sutfin | P. Cosgrove | Ann T Willauer
[1] P. Thompson,et al. High-density lipoprotein metabolism in runners and sedentary men. , 1984, JAMA.
[2] S. Yamashita,et al. Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates high-density lipoprotein concentration and composition. , 1991, Metabolism: clinical and experimental.
[3] Skinner Er,et al. Cholesterol-loading of peripheral tissues alters the interconversion of high density lipoprotein subfractions in rabbits. , 1996 .
[4] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[5] D. Rader,et al. Characterization of high-density apolipoprotein particles A-I and A-I:A-II isolated from humans with cholesteryl ester transfer protein deficiency. , 1995, European journal of biochemistry.
[6] Y. Fragoso,et al. The role of subfractions of high density lipoprotein in the in vivo transport of cholesterol from cholesterol-loaded hepatic and peripheral endothelial cells in the New Zealand white rabbit. , 1993, Comparative biochemistry and physiology. B, Comparative biochemistry.
[7] V. Dias,et al. Dual-precipitation method evaluated for determination of high-density lipoprotein (HDL), HDL2, and HDL3 cholesterol concentrations. , 1988, Clinical chemistry.
[8] S. Horiuchi,et al. Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. , 1995, Journal of lipid research.
[9] Mark E. McGovern,et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). , 2003 .
[10] A. Tall,et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.
[11] D. Rader,et al. Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[12] A. Tall,et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. , 1996, The Journal of clinical investigation.
[13] Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001 .
[14] D R Shapiro,et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2000, Circulation.
[15] A. Tall,et al. The Orphan Nuclear Receptor LRH-1 Potentiates the Sterol-mediated Induction of the Human CETP Gene by Liver X Receptor* 210 , 2001, The Journal of Biological Chemistry.
[16] P. Barter,et al. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. , 2003, Atherosclerosis.
[17] H. Greten,et al. Biotinyl-high-density lipoproteins as a probe for the determination of high-density lipoprotein turnover in humans. , 1990, Biochimica et biophysica acta.
[18] A. Tall,et al. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI. , 1995, The Journal of clinical investigation.
[19] S. Yamashita,et al. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. , 2000, Atherosclerosis.
[20] M C Hjortland,et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.
[21] A. Tall,et al. Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency. , 1991, Atherosclerosis.
[22] D. Gordon,et al. High-Density Lipoprotein Cholesterol and Cardiovascular Disease , 2005 .
[23] M. Kamada,et al. Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits* , 1998, The Journal of Biological Chemistry.
[24] Vesa Manninen,et al. Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment , 1992, Circulation.
[25] A Kagan,et al. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. , 1976, The New England journal of medicine.
[26] L. Tenkanen,et al. Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study , 1992 .
[27] S. Yamashita,et al. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. , 1994, Journal of biochemistry.
[28] A. Callow,et al. Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[29] H. Suzuki,et al. Quantitative and compositional changes in high density lipoprotein subclasses in patients with various genotypes of cholesteryl ester transfer protein deficiency. , 1997, Journal of lipid research.
[30] J. Paul,et al. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[31] K. Wakitani,et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.
[32] J. Moberly,et al. Low level quantification of cholesteryl ester transfer protein in plasma subfractions and cell culture media by monoclonal antibody-based immunoassay. , 1995, Journal of lipid research.
[33] H. Mabuchi,et al. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. , 2002, Clinical science.
[34] H. Suzuki,et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. , 1998, Preventive medicine.
[35] A. Tall,et al. Plasma kinetics of cholesteryl ester transfer protein in the rabbit. Effects of dietary cholesterol. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[36] D. Gordon,et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.
[37] D. B. Zilversmit,et al. Cholesteryl ester exchange protein in human plasma isolation and characterization. , 1978, Biochimica et biophysica acta.
[38] A. Zwinderman,et al. Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.